Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Francisco D. Salva
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Beta
- -1.07
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -12.63
Financials
Revenue
$0.00-100.0%Net Income
$-3.35MEBITDA
$3.35MFree Cash Flow
$-3.33MEPS (diluted)
$-0.17Shares Outstanding (diluted)
19.30M+31805.7%Operating Expenses
$3.42MCash & Debt
$6.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-10.96M | $-2.25 |
| 2024 | $7.5K | $-8.97M | $-15.78 |
| 2023 | $686.0K | $-11.28M | $-208.74 |
| 2022 | $284.0K | $-10.68M | $-222.33 |
| 2021 | $110.0K | $-8.94M | $-193.55 |
Valuation
AZTRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsprnewswire.com·5d ago·Neutral
… Trial to Cohort 2 Following Safety Review Committee Clearance BRANFORD, Conn., Oct. 1, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the completion of Cohort 1 in its Phase 1/2 clinical trial evaluating ATR04-484 as a potential treatment for EGFR inhibitor (EGFRi)-associated skin rash.
View source ↗ - Newsprnewswire.com·46d ago·Positive
…ins Compliance with NYSE American Continued Listing Standards BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE American") confirming that the Company has regained compliance with all of the N…
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates BRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.02 per share
Typical surprise -129.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.17 vs $-0.12miss
- Tue, May 12$-0.25 vs $-0.01miss
- Mon, Mar 2$-1.15 vs $-0.37miss
- Wed, Nov 12$-0.67 vs $-0.79beat
- Mon, Aug 11$-1.20 vs $-1.40beat
- Fri, Mar 21$-2.06 vs $-0.51miss
Estimates and results for AZTR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AZTR officers and directors.
- Bought
- $15.6m
- Sold
- $411k
19 trades
2 trades
- Salva Francisco D.bought
- Salva Francisco D.bought
- Salva Francisco D.bought
- Staskey Normbought
- Whitfill Travisbought
- Staskey Normbought
- Salva Francisco D.bought
- Kreis Leslie W.bought
79 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AZTR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.